Etoposide phosphate
As of the edition of 20 October 2026, Etoposide phosphate is a small molecule: marketed, first approved in 1996 (US); acts on TOP2A; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Etopophos Preservative Free
- First approved
- 17 May 1996 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Bristol Myers Squibb; 2 holders in all
- Registered trials
- 85, 8 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Nervous system; Urinary and reproductive; Hormones
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Etoposide phosphate.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | P11388 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 3 | 0 | 0 |
| Phase 1 | 17 | 8 | 2 | 3 |
| Phase 2 | 33 | 16 | 6 | 4 |
| Phase 3 | 20 | 5 | 8 | 1 |
| Phase 4 | 8 | 6 | 0 | 0 |
| All trials | 85 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Cheplapharm Arzneimittel | Acquired holder | 2019 to now |
| Bristol Myers Squibb | Originator | 1996 to 2019 |